Oklahoma State University Oklahoma City

InstitutionResearch output, impact & collaborations

Oklahoma State University Oklahoma City is a research organisation in Oklahoma City, US. OpenAlex records 18,271 works and 438,822 citations for it. 3,862 researchers list it as their most recent affiliation.

18,271

Works

438,822

Citations

3,862

Researchers

73.4

Avg h-index

IDs:ROR OpenAlex

How has Oklahoma State University Oklahoma City's publication output changed over time?

ScholarIQpublication output · 2003–2023

Output grew0% over the shown period — from 1 works in 2003 to 1 in 2023.

200320112015201720192023

What are the most-cited papers on Oklahoma State University Oklahoma City?

ScholarIQmost cited works

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang

New England Journal of Medicine. 20112,398 CitationsOPEN ACCESS

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen

Journal of Clinical Oncology. 20032,059 Citations

Inherited Mutations in Women With Ovarian Carcinoma

Barbara M. Norquist, Maria I. Harrell, Mark F. Brady, Tom Walsh, Ming K. Lee, Süleyman Gülsüner, Sarah S. Bernards, Silvia Casadei, Yi Qian, Robert A. Burger, John K. Chan, Susan A. Davidson, Robert S. Mannel, Paul DiSilvestro, Heather A. Lankes, Nilsa C. Ramirez, Mary‐Claire King, Elizabeth M. Swisher, Michael J. Birrer

JAMA Oncology. 2015771 CitationsOPEN ACCESS

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian

New England Journal of Medicine. 2023733 CitationsOPEN ACCESS

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Joan L. Walker, Byoung‐Gie Kim, Keiichi Fujiwara, Krishnansu S. Tewari, David M. O’Malley, Susan A. Davidson, Stephen C. Rubin, Paul DiSilvestro, Karen Basen‐Engquist, Helen Huang, John K. Chan, Nick M. Spirtos, Raheela Ashfaq, Robert S. Mannel

The Lancet Oncology. 2017608 CitationsOPEN ACCESS